Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

  1. Litton, J.K.
  2. Hurvitz, S.A.
  3. Mina, L.A.
  4. Rugo, H.S.
  5. Lee, K.-H.
  6. Gonçalves, A.
  7. Diab, S.
  8. Woodward, N.
  9. Goodwin, A.
  10. Yerushalmi, R.
  11. Roché, H.
  12. Im, Y.-H.
  13. Eiermann, W.
  14. Quek, R.G.W.
  15. Usari, T.
  16. Lanzalone, S.
  17. Czibere, A.
  18. Blum, J.L.
  19. Martin, M.
  20. Ettl, J.
Revue:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Année de publication: 2020

Volumen: 31

Número: 11

Pages: 1526-1535

Type: Article

DOI: 10.1016/J.ANNONC.2020.08.2098 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus